Peptide Comparison
MK-677 vs Tesamorelin + Ipamorelin
Editorial breakdown of mechanism, evidence, decision criteria, and the misconceptions worth calling out.
Data-derived verdict
Tesamorelin + Ipamorelin has stronger documented evidence (FDA-Approved (component)) than MK-677 (Phase 3 (not approved)) while both occupy the gh-secretagogue class. When clinical-evidence tier is the deciding factor, Tesamorelin + Ipamorelin is the safer pick. MK-677 may still fit a specific research framing the higher-evidence option does not cover: cost, dosing convenience, jurisdictional access, or a particular off-label use case.
Evidence at a glance
FDA-approved Phase 3 Phase 2 / approved abroad Anecdotal + animal Preclinical / flagged
Side-by-side
| MK-677 | Tesamorelin + Ipamorelin | |
|---|---|---|
| Class | Oral non-peptide ghrelin receptor agonist | FDA-approved GHRH analog (Tesamorelin) + selective GHRP (Ipamorelin) blend |
| Drug class | Growth Hormone Secretion | Growth Hormone Secretion |
| Mechanism | GHS-R1a agonist; stimulates pulsatile GH/IGF-1 release; orally bioavailable spiropiperidine | Tesamorelin's trans-3-hexenoyl modification gives a longer-acting pituitary GHRH-R stimulus than CJC no-DAC, paired with Ipamorelin's GHS-R1a pulse to layer pituitary GH release. The Tesamorelin arm carries the strongest single-agent visceral-fat data (EMERALD); the Ipamorelin arm contributes pulse amplitude without cortisol/prolactin spillover. |
| Route | Oral | SC injection |
| Half-life | ~24 hrs | Tesamorelin ~26 min (plasma); Ipamorelin ~2 hrs |
| Dosage (research) | 12.5 mg oral daily (community starting dose to mitigate water retention and appetite increase, escalate to label dose 25 mg/day per MK-0677-014 Phase 3 protocol) | 1 mg Tesamorelin + 200 mcg Ipamorelin SC nightly (5 nights/wk). Cycle 12-16 weeks on / 4-6 weeks off |
| Evidence tier | Phase 3 (not approved) | FDA-Approved (component) |
| Research depth | 168 indexed | 2 indexed |
| Availability | Research Chemical | Compounding Restricted |
| Reported risks | Increased hunger; water retention; insulin resistance risk; lethargy; CHF risk (elderly trials) | Tesamorelin component carries FDA-label pancreatitis and hyperglycaemia warnings; injection-site reactions; theoretical IGF-1 elevation; cost is high (Tesamorelin compounded form is expensive) |
Reported research data only. "Studied for" and "reported in literature" describe published research focus, not clinical recommendation. Most peptides catalogued here are not FDA-approved for human use.
Frequently asked questions
Should I pick MK-677 or Tesamorelin + Ipamorelin?
Tesamorelin + Ipamorelin has stronger documented evidence (FDA-Approved (component)) than MK-677 (Phase 3 (not approved)) while both occupy the gh-secretagogue class. When clinical-evidence tier is the deciding factor, Tesamorelin + Ipamorelin is the safer pick. MK-677 may still fit a specific research framing the higher-evidence option does not cover: cost, dosing convenience, jurisdictional access, or a particular off-label use case.
What is the difference between MK-677 and Tesamorelin + Ipamorelin?
MK-677 is classed as Oral non-peptide ghrelin receptor agonist; Tesamorelin + Ipamorelin is classed as FDA-approved GHRH analog (Tesamorelin) + selective GHRP (Ipamorelin) blend. Reported mechanism: MK-677, GHS-R1a agonist; stimulates pulsatile GH/IGF-1 release; orally bioavailable spiropiperidine; Tesamorelin + Ipamorelin, Tesamorelin's trans-3-hexenoyl modification gives a longer-acting pituitary GHRH-R stimulus than CJC no-DAC, paired with Ipamorelin's GHS-R1a pulse to layer pituitary GH release. The Tesamorelin arm carries the strongest single-agent visceral-fat data (EMERALD); the Ipamorelin arm contributes pulse amplitude without cortisol/prolactin spillover. Reported half-life: MK-677, ~24 hrs; Tesamorelin + Ipamorelin, Tesamorelin ~26 min (plasma); Ipamorelin ~2 hrs. Routes in published studies: MK-677, Oral; Tesamorelin + Ipamorelin, SC injection.
Which has stronger evidence, MK-677 or Tesamorelin + Ipamorelin?
Tesamorelin + Ipamorelin has the stronger evidence base on PeptideHelper.org's five-step evidence scale, which runs from preclinical to FDA-approved. MK-677 is graded Phase 3 (not approved), with 5 cited sources on its reference page and 168 indexed studies. Tesamorelin + Ipamorelin is graded FDA-Approved (component), with 3 cited sources on its reference page and 2 indexed studies.
Which is more accessible, MK-677 or Tesamorelin + Ipamorelin?
Neither MK-677 nor Tesamorelin + Ipamorelin is an FDA-approved drug. Catalog status: MK-677, Research Chemical; Tesamorelin + Ipamorelin, Compounding Restricted. FDA lists MK-677 in category 2 of its bulk-substance compounding policy (503A; 503B, added 503A: September 29, 2023 503B: December 29, 2022).
Are MK-677 and Tesamorelin + Ipamorelin ever combined?
MK-677 and Tesamorelin + Ipamorelin appear together in no stack catalogued on PeptideHelper.org, and the interaction engine raises no flag for the pair.
Open the PeptideHelper.org compare tool to add more compounds to this side-by-side and filter by evidence tier interactively.
Loading interactive view…